LCB-2853 is primarily utilized in the field of oncology research, where it serves as a potent inhibitor targeting specific protein kinases involved in cancer cell proliferation and survival. Its application is particularly significant in preclinical studies aimed at understanding the mechanisms of tumor growth and metastasis. Researchers employ LCB-2853 to evaluate its efficacy in suppressing kinase activity, which can lead to the identification of potential therapeutic strategies for various cancers. Additionally, it is used in combination studies with other anticancer agents to assess synergistic effects and enhance treatment outcomes. The compound's role in modulating signaling pathways also makes it valuable in studies focused on drug resistance, helping to develop novel approaches to overcome this challenge in cancer therapy.